Xconomy

MARCH 1, 2019

biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.

Report 83

Report Pricing Sales San Diego 83

Xconomy

DECEMBER 21, 2018

It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

Pricing 73

Pricing Sales Study News 73

Xconomy

JULY 30, 2019

About this time last year, DNA sequencing giant Illumina upped its financial projections, estimating its sales would grow 20 percent year-over-year. On Monday, Illumina (NASDAQ: ILMN ) informed the markets that it had overshot the mark with its 2019 estimates. It exceeded that goal, with revenue rising 21 percent to $3.33

Study 59

Study News Demand Tool 59

Xconomy

AUGUST 26, 2016

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing.

Pricing 40

Pricing Thousand Oaks Startup Research 40